Correlation Between Spineguard and Mastrad
Can any of the company-specific risk be diversified away by investing in both Spineguard and Mastrad at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spineguard and Mastrad into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Spineguard and Mastrad, you can compare the effects of market volatilities on Spineguard and Mastrad and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spineguard with a short position of Mastrad. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spineguard and Mastrad.
Diversification Opportunities for Spineguard and Mastrad
-0.42 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Spineguard and Mastrad is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Spineguard and Mastrad in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mastrad and Spineguard is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spineguard are associated (or correlated) with Mastrad. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mastrad has no effect on the direction of Spineguard i.e., Spineguard and Mastrad go up and down completely randomly.
Pair Corralation between Spineguard and Mastrad
Assuming the 90 days trading horizon Spineguard is expected to generate 0.86 times more return on investment than Mastrad. However, Spineguard is 1.16 times less risky than Mastrad. It trades about 0.0 of its potential returns per unit of risk. Mastrad is currently generating about -0.02 per unit of risk. If you would invest 59.00 in Spineguard on August 27, 2024 and sell it today you would lose (38.00) from holding Spineguard or give up 64.41% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Spineguard vs. Mastrad
Performance |
| Timeline |
| Spineguard |
| Mastrad |
Spineguard and Mastrad Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Spineguard and Mastrad
The main advantage of trading using opposite Spineguard and Mastrad positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spineguard position performs unexpectedly, Mastrad can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mastrad will offset losses from the drop in Mastrad's long position.| Spineguard vs. Biomerieux SA | Spineguard vs. Eurofins Scientific SE | Spineguard vs. Sartorius Stedim Biotech | Spineguard vs. SEB SA |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Complementary Tools
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |